Nuvectis Pharma opened lower at $20.82, compared with its previous close of $21.00. In the last trading session, the stock traded between $20.16 and $21.18. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Nuvectis Pharma is now worth
$ 623.17
Giving a profit of
$ 523.17 (523.17%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.75 (-3.56%)
Day High
$21.18
Day Low
$20.16
Day Open
$20.82
Prev Close
$21.00
Volume
1,76,038
1W Return
9.74%
1M Return
2.83%
3M Return
4.01%
6M Return
83.12%
1Y Return
234.21%
Fundamentals
Market Cap ($ Mn)
696
PE Ratio
-
PB Ratio
69.75
PEG Ratio
-
ROE
-146.96%
ROCE
-153.25%
EPS (TTM)
$-0.87
Investment Returns
1 Week
9.74%
1 Month
2.83%
3 Months
4.01%
6 Months
83.12%
9 Months
130.67%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
4Nov
Nuvectis Pharma Q3FY26 Results: EPS misses estimate by 325%
Nuvectis Pharma reported Q3FY26 loss per share of $(1.02). EPS missed analyst consensus estimate of $(0.24) by 325%. Losses widened 131.82% YoY from $(0.44) in Q3FY25.
8 days ago
22Aug
Nuvectis Pharma files base prospectus for $200m securities sale
Nuvectis Pharma filed a base prospectus with the SEC. The filing covers the offer and sale of up to $200 million in securities. Specific security types and terms will be defined in future supplements.
2mo ago
23Jul
Nuvectis Pharma's ciprocopan wins China NMPA approval for PNH treatment
Nuvectis Pharma announced NMPA approval for ciprocopan, a once-daily oral Factor B inhibitor for treatment-naive PNH patients in China. The approval follows superior Phase 3 results against eculizumab, with 59.5% achieving hemoglobin targets vs 8.3%. Nuvectis holds exclusive rights outside Greater China, India, and parts of Southeast Asia under a June 2026 agreement.
3mo ago
6Jul
Roth Capital raises Nuvectis target to $33
Roth Capital analyst Jonathan Aschoff maintained a Buy rating on Nuvectis Pharma and raised the price target to $33 from $20. This comes as Nuvectis priced a $100 million public offering of 5,000,000 shares at $20.00 per share, with an expected closing date of July 1, 2026.
4mo ago
23Jun
Nuvectis Pharma surges 20% on Haisco license deal
Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 19.61% to a 52-week high of $16.53 following a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to NXP100 and NXP200. The deal involves up to $40 million in upfront payments and $1.421 billion in potential milestone payments. NXP100 is a late-stage Complement Factor B inhibitor for PNH and IgAN, while NXP200 is a paradox-breaker BRAF inhibitor for various cancers.
4mo ago
22Jun
HC Wainwright raises Nuvectis Pharma price target to $39
HC Wainwright & Co. analyst Joseph Pantginis maintained a Buy rating on Nuvectis Pharma and raised the price target to $39 from $13.
